azacitidine has been researched along with Acute Biphenotypic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Li, M; Qiu, H; Sun, A; Wu, D; Wu, X; Zhang, J; Zhou, L | 1 |
| Choi, MY; Kim, KH; Lee, JY; Lee, SM; Lee, WS | 1 |
2 other study(ies) available for azacitidine and Acute Biphenotypic Leukemia
| Article | Year |
|---|---|
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nausea; Oncogene Proteins, Fusion; Sulfonamides; Transplantation, Haploidentical; Treatment Outcome; Vomiting | 2020 |
Mixed-phenotype acute leukemia treated with decitabine.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Biopsy; Bone Marrow Examination; Cell Lineage; Decitabine; Female; Humans; Leukemia, Biphenotypic, Acute; Phenotype; Remission Induction; Treatment Outcome | 2016 |